Beijing Sun Novo Pharmaceutical Research Co Ltd Capital Reinvestment Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd capital reinvestment ratio. Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Capital Reinvestment Ratio of 0.06x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥76.07 Million) in capital expenditures (CN¥4.69 Million). Check Beijing Sun Novo Pharmaceutical Research investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Capital reinvestment ratio of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. This chart tracks Beijing Sun Novo Pharmaceutical Research Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Also explore Beijing Sun Novo Pharmaceutical Research (688621) equity growth momentum to track the company's year-over-year net asset growth rate.
Beijing Sun Novo Pharmaceutical Research Co Ltd Capital Reinvestment Ratio by Year (2017–2025)
Beijing Sun Novo Pharmaceutical Research Co Ltd capital reinvestment ratio by year from 2017 to 2025. For the full cash flow conversion analysis, see 688621 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | CN¥93.21 Million | CN¥42.43 Million | ▼ -52.2% |
| 2024 | 0.95x | CN¥32.02 Million | CN¥30.48 Million | ▲ +21.2% |
| 2023 | 0.79x | CN¥92.86 Million | CN¥72.96 Million | ▼ -21.4% |
| 2022 | 1.00x | CN¥103.96 Million | CN¥103.87 Million | ▲ +3.8% |
| 2021 | 0.96x | CN¥88.25 Million | CN¥84.96 Million | ▲ +124.3% |
| 2020 | 0.43x | CN¥62.99 Million | CN¥27.03 Million | ▼ -4.8% |
| 2019 | 0.45x | CN¥56.97 Million | CN¥25.67 Million | ▲ +21.1% |
| 2018 | 0.37x | CN¥44.11 Million | CN¥16.41 Million | ▼ -85.8% |
| 2017 | 2.62x | CN¥8.01 Million | CN¥20.96 Million | — |